Enanta Pharmaceuticals (ENTA)
(Delayed Data from NSDQ)
$13.23 USD
-0.77 (-5.50%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $13.22 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
Price, Consensus and EPS Surprise
ENTA 13.23 -0.77(-5.50%)
Will ENTA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ENTA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ENTA
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates
Strength Seen in Enanta Pharmaceuticals (ENTA): Can Its 13.8% Jump Turn into More Strength?
ENTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Enanta, OneConnect Financial, KNOT Offshore, Hippo Holdings and H World
5 Secret Santa Stocks to Pop Surprise Returns
Wall Street Analysts Predict a 108.12% Upside in Enanta Pharmaceuticals (ENTA): Here's What You Should Know
Other News for ENTA
Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
Inventiva Phase 2 study for MASH drug meets primary endpoint
Madrigal climbs amid hopes for new NASH drug; B. Riley upgrades
Madrigal and liver drug developers fall ahead of FDA decision on NASH therapy
Madrigal granted FDA approval for NASH therapy